Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA

Documenti analoghi

• Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
  di: Raedler, Lisa A.
  Pubblicazione: (2016)
• FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz’s Filgrastim Faces Naming and Court Hurdles
  di: Barlas, Stephen
  Pubblicazione: (2015)
• FDA and EMA Biosimilar Approvals
  di: Jung, Emily H., et al.
  Pubblicazione: (2019)
• Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies
  di: Harbeck, Nadia, et al.
  Pubblicazione: (2018)
• The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
  di: Gherghescu, Ioana, et al.
  Pubblicazione: (2020)